FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 1997 WARNER-LAMBERT COMPANY (Exact name of registrant as specified in its charter) Delaware 1-3608 22-1598912 (State or other (Commission (IRS Employer Jurisdiction of File Number) Identification incorporation) No.) 201 Tabor Road, Morris Plains, New Jersey 07950 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (973) 540-2000 Item 5. Other Events. On December 1, 1997, the Registrant issued a press release stating that the Parke-Davis division of the Registrant announced new label changes for REZULIN (troglitazone), its drug for type 2 diabetes. These changes will prominently recommend that physicians monitor patients more frequently for signs of liver dysfunction. The Company does not believe that the labeling changes will appreciably diminish the population of patients eligible for this important medication, but will be assessing, over the next few months, what effect, if any, the labeling changes may have on expected sales and earnings for 1998. The foregoing summary is qualified in its entirety by the complete text of the press release dated December 1, 1997, which is attached hereto. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. (c) Exhibits (99) Additional Exhibits. (a) Press Release dated December 1, 1997. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WARNER-LAMBERT COMPANY (Registrant) Date: December 1, 1997 By: JOSEPH E. LYNCH Vice President and Controller (Principal Accounting Officer) Exhibit Index Exhibit No. Exhibit Page No. (99) Additional Exhibits. (a) Press Release dated December 1, 1997 Exhibit 99(a)